Vismodegib in Treating Patients With Advanced Chondrosarcomas

Phase 2 Active not recruiting 45 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well vismodegib works in treating patients with chondrosarcomas that have spread to other places in the body and usually cannot be cured or controlled with treatment. Drugs used in chemotherapy, such as vismodegib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Timeline

Start: 2010-12-21
Primary completion: 2018-06-30
Completion: 2026-07-21

Outcome

Missed primary endpoint

paper GDC-0449 did not meet the primary end point of this trial. PMID 24170610 ↗

Publications

Italiano A, Le Cesne A, Bellera C, Piperno-Neumann S, Duffaud F, Penel N, Cassier P, Domont J, Takebe N, Kind M, Coindre JM, Blay JY, Bui B. GDC-0449 in patients with advanced chondrosarcomas: a French Sarcoma Group/US and French National Cancer Institute Single-Arm Phase II Collaborative Study. Ann Oncol. 2013 Nov;24(11):2922-6. doi: 10.1093/annonc/mdt391.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vismodegib	Small molecule	150 mg	Oral